NCK1-AS1 promotes the proliferation, migration, invasion, and EMT of non-small cell lung cancer by regulating the miR-361-5p/ADAM10 axis. 2023

Bingchen Wu, and Zizong Wang, and Hanlin Xu, and Xiangyang Chu, and Qiwen Jiang
Department of Oncology, Hospital of Chinese Medicine of Changxing County, Huzhou, Zhejiang, China.

Lung cancer, one of the most frequently diagnosed cancers, causes a huge number of mortalities globally. Among lung cancers, non-small cell lung cancer (NSCLC) is the most recorded. Despite accumulating research, the molecular basis of NSCLC progression remains poorly known. Therefore, we aim to assess the function of NCK1-AS1 in NSCLC and elucidate the molecular mechanism. Firstly, we quantified the NCK1-AS1 level in tumors and adjacent healthy tissues. NCK1-AS1 was significantly upregulated in NSCLC tumors, which was associated with poor prognosis in patients. Silencing NCK1-AS1 significantly inhibited the proliferation, migration, and invasion, as well as the EMT of NSCLC cell lines. Starbase bioinformatic prediction revealed that NCK1-AS1 targets miR-361-5p which acts to regulate ADAM10 gene expression. Our result showed that NCK1-AS1 upregulation markedly reduced miR-361-5p mRNA expression, while increasing ADAM10 expression. For the first time, we demonstrated that NCK1-AS1 regulates the miR-361-5p/ADAM10 axis, thereby promoting NSCLC progression. NCK1-AS1 might be developed as a therapeutic target for treating NSCLC.

UI MeSH Term Description Entries

Related Publications

Bingchen Wu, and Zizong Wang, and Hanlin Xu, and Xiangyang Chu, and Qiwen Jiang
November 2020, Pathology, research and practice,
Bingchen Wu, and Zizong Wang, and Hanlin Xu, and Xiangyang Chu, and Qiwen Jiang
November 2020, Pathology, research and practice,
Bingchen Wu, and Zizong Wang, and Hanlin Xu, and Xiangyang Chu, and Qiwen Jiang
January 2020, Cancer cell international,
Bingchen Wu, and Zizong Wang, and Hanlin Xu, and Xiangyang Chu, and Qiwen Jiang
January 2018, OncoTargets and therapy,
Bingchen Wu, and Zizong Wang, and Hanlin Xu, and Xiangyang Chu, and Qiwen Jiang
January 2022, BMC pulmonary medicine,
Bingchen Wu, and Zizong Wang, and Hanlin Xu, and Xiangyang Chu, and Qiwen Jiang
January 2022, Anti-cancer drugs,
Bingchen Wu, and Zizong Wang, and Hanlin Xu, and Xiangyang Chu, and Qiwen Jiang
February 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Bingchen Wu, and Zizong Wang, and Hanlin Xu, and Xiangyang Chu, and Qiwen Jiang
December 2021, Bioengineered,
Bingchen Wu, and Zizong Wang, and Hanlin Xu, and Xiangyang Chu, and Qiwen Jiang
September 2021, Experimental and therapeutic medicine,
Bingchen Wu, and Zizong Wang, and Hanlin Xu, and Xiangyang Chu, and Qiwen Jiang
July 2021, Cancer cell international,
Copied contents to your clipboard!